A revolution in Neuro Precision Diagnostics
A 1st time right diagnosis
CLARIK offers automated, timely and objective diagnosis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, through reliable, affordable, and accessible AI-based neuroimaging biomarkers.
Clinical decision support systems (CDSS’s) providing a report with differential diagnosis and staging of the disease
Precision tool for pharmaceutical companies, allowing accurate patients’ stratification, eligibility and disease progression on clinical studies
Research precision diagnostics platform for new digital biomarkers
A pre-condition to reach personalized medicine is precision diagnostics. Hand in hand with the need for more effective treatments and cure, reaching an earlier and accurate diagnosis is critical. Today, there is no single clinical test for the conclusive diagnosis of most neurodegenerative diseases, such as Alzheimer’s or Parkinson’s Disease.
Our Solutions Pipeline
a single diagnostic test, a 1st time right diagnosis, that is specific and sensitive, widely available (capitalizing on mainstream hospital equipment, MRI), allowing an earlier and accurate diagnosis and staging of these illnesses and response to therapy.
Biomarkers in Clinical Stage
CLARIK is currently in clinical stages to secure certification as a Class II Medical Device for biomarkers targeting Alzheimer’s and Parkinson’s Disease.
Our scientific team contribute to the growth of the research community. Here a list of some of the the scientific publications they were involved in.
Ribeiro et al. (2015), Multimodal Imaging Brain Connectivity Analysis (MIBCA) toolbox. PeerJ 3:e1078; DOI 10.7717/peerj.1078
RIBEIRO et al.: MULTIMODAL IMAGING OF BRAIN CONNECTIVITY USING THE MIBCA TOOLBOX, IEEE TRANSACTIONS ON NUCLEAR SCIENCE, VOL. 62, NO. 3, JUNE 2015